As mutations in Lynch syndrome predisposing genes are usually associated with loss of protein expression in the tumor, we performed immunohistochemistry for the MSH2 and MSH6 proteins in the prostate tumors of the patients HPC371 and HPC332, respectively, and no loss of expression was found, rendering the MSH2 and MSH6 mutations as probably not associated with PrCa development in these patients. This evidence concerns the gene MSH2 and neoplasm.